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Background: The hepatitis C virus (HCV) is known to infect the brain, however, the
findings based on associated neuropsychiatric syndrome are controversial and the
association itself remains unclear. Gender research in HCV infection is limited, failing
to integrate the role of gender differences in neurocognitive syndrome. The aim of this
study was to characterize psychological and neurocognitive profiles in HCV-infected
patients before treatment and to explore gender differences in those profiles, as well as
the impact of disease severity.
Methods: A total of 86 patients diagnosed with chronic hepatitis C were included.
Depression and anxiety were assessed using Hamilton anxiety scale (HAM-A),
Hamilton depression scale (HAM-D), Beck Depression Inventory (BDI). For cognition, a
neuropsychological battery to measure attention, concentration and memory was used,
and executive function components validated for the Portuguese population was also
used before starting treatment. To identify the disease severity, platelet ratio index, and
FibroScan R© were used.
Results: A statistically significant gender effect was found on HAM-A (B = 0.64, CI:
0.17–1.11) and HAM-D (B = 0.62, CI: 0.14–1.09), with women scoring higher compared
to men. Regarding neuropsychological scores, significant differences between gender
were identified in executive functions measured by Trail Making Test (TMT B) (B = 0.48,
CI: 0.02–0.97), TMT B-A (B = 0.26, CI:−39.2 to−3.7) and in digit span total (B =−0.52,
CI: −1.0 to −0.04), with women performing worse than men. Controlling for years of
substance dependence, TMT-B and TMT B-A showed significant gender differences.
Regarding the presence or absence of substance dependence, only HAM-A and HAM-
D remained significant. For categorical variables, Digit Span Total was also influenced
by gender, with women being more likely to be impaired: odds ratio (OR) = 7.07,
CI: 2.04–24.45), and a trend was observed for Digit Span Backward (OR = 3.57,
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CI: 1.31–9.75). No significant differences were found between disease severity and
neurocognitive performance.
Conclusion: Data suggest that gender has an influence on depression, anxiety and
cognitive functions with women showing greater impairment compared with men. This
effect seems to be influenced by substance dependence.
Keywords: hepatitis C, neurocognition, anxiety, depression, gender, disease severity
INTRODUCTION
Hepatitis C virus (HCV) is one of the most important infections
worldwide, with 71 million people infected (Polaris Observatory
et al., 2017). Despite the advent of HCV therapies and high
rates of cure, if not treated, HCV acute infection tends to
progress to chronic state, hepatic cirrhosis (10 to 40%) and
hepatocellular carcinoma, which tend to be clinical indications
for liver transplant (1 to 5% per year) (Monaco et al., 2015).
Hepatitis C virus patients frequently present neuropsychiatric
symptoms, including fatigue, anxiety, depression, and
neurocognitive impairment, that have been associated with
negative treatment outcomes (Monaco et al., 2015; Dirks et al.,
2017; Yarlott et al., 2017). Several studies reported that HCV
associated neuropsychological impairments are independent
of liver disease stage (excluding cirrhosis) (Monaco et al.,
2015; Yarlott et al., 2017), suggesting that, in chronic patients,
HCV infection itself might directly cause cerebral dysfunction,
contributing to cognitive deficits in patients (Grover et al., 2012).
Therefore, the neurocognitive profile of these patients before
treatment needs to be addressed, due to the possible implications
on the treatment course (e.g., non-adherence-like behavior due
to cognitive dysfunction). Additionally, it is important to address
other risk factors that can have a negative impact on cognition.
Despite the eventual effects of antiviral medication on cognition,
the high rate of substance abuse and the prevalence of psychiatric
disorders among HCV-infected patients are important factors
associated with cognitive impairment that compromises
adherence and treatment efficacy (Wie˛dłocha et al., 2017).
Most of the patients with HCV consistently report a significant
reduction in health-related quality of life, in comparison
with healthy controls (Adinolfi et al., 2017). The psychiatric
symptomatology in chronic hepatitis C, in particular depression,
is twice as high as in the general population, and it is
probably one of the major factors for decreasing quality of life,
treatment discontinuation and/or negative treatment outcomes
(Monaco et al., 2015).
According to several studies, it has been hypothesized that
depression and cognitive impairment might be associated with
HCV neurotoxicity (Adinolfi et al., 2015). Recent studies with
interferon-free treatment showed that HCV patients presented
neuropsychiatric symptoms like fatigue, insomnia, anxiety,
depression, and cognitive dysfunction (Gritsenko and Hughes,
2015; Smith et al., 2015; Chasser et al., 2017), supporting the HCV
neurotoxicity hypothesis.
In untreated HCV patients, emotional distress and depressive
disorders suggest the role of HCV itself in the onset of these
neuropsychiatric manifestations (Alavi et al., 2012). In a recent
review, the “hepatitis C brain syndrome” was identified as being
composed of cognitive impairment, fatigue, and depression.
This syndrome is probably generated by peripheral immune
responses, affecting the central nervous system (CNS) by a
neuroinflammatory response associated with CNS HCV infection
and also by negative life events and other psychogenic stressors
(Yarlott et al., 2017).
Neurocognitive impairment, one of the most common
extrahepatic manifestations of HCV, can lead to subtle changes
in processing speed, memory, and cognitive performance
(attention, concentration, psychomotor speed, and verbal
fluency), and up to 50% of HCV-infected patients can develop
clinical or subclinical manifestations of this dysfunction (Lowry
et al., 2010; Ferri et al., 2016). Cognitive impairments were
previously thought to be associated with the development of
hepatic encephalopathy (Gaeta et al., 2013). However, their
presence was demonstrated in the absence of advanced liver
disease, as well as in the absence of human immunodeficiency
virus (HIV) coinfection, depression or substance dependence
(Weissenborn et al., 2004; Kuhn et al., 2017; Yarlott et al., 2017).
HCV is known to infect the brain; however, findings from
studies on associated neurocognitive changes are controversial
and it remains unclear whether HCV eradication improves
neurocognitive performance (Kuhn et al., 2017).
Regarding gender differences, women with HCV seem to
experience stigma, concerns about confidentiality, treatment
side effects and lack of engagement with health services,
more so than men (Harris and Rhodes, 2013). However,
the gender differences research in symptoms profile, as
well as in treatment response and treatment adherence, is
scarce, albeit crucial to improving medical and psychological
integrated interventions.
This study aimed to characterize psychological and
neurocognitive profiles in HCV-infected patients before
treatment, and to describe gender differences as well as the
impact of disease severity in those profiles.
MATERIALS AND METHODS
This research is part of a larger longitudinal protocol
including two assessment times, before and after HCV antiviral
medication. It was submitted to and approved by the Centro
Hospitalar Universitário Lisboa Norte Ethics Committee
(Ref. 0536) and the Portuguese Data Protection Authority
(No. 6331/2012).
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If eligible, subjects were informed about the nature of the study
and their voluntary cooperation. After confidentiality assurance,
written informed consent was obtained.
Recruitment of Participants
A total of 86 patients diagnosed with chronic hepatitis C were
selected from an outpatient clinic through a convenience
procedure (Viral Hepatitis Clinic at the Hospital de
Santa Maria, Lisbon).
The inclusion criteria were: minimum formal schooling
completed with success (at least 4 years education or fluency
in reading and writing); ages between 18 and 65 years-
old; diagnosis of chronic hepatitis C with detectable HCV
RNA viral load for at least 6 months. The exclusion criteria
were: presence of neurological or psychiatric disorders
that may induce cognitive deficits; major depression
according to DSM-V; consumption of opiates, cocaine
and/or other recreational drugs in the 6 months prior
to the beginning of the assessment; use of medication
that may interfere with the study objectives; history of
neurological, infectious or tumoural pathology or systemic
illness with an impact at CNS level; a Mini-Mental State
Examination (MMSE) score below the cut-off for dementia
in the Portuguese population; hepatic cirrhosis or severe
physical deterioration incompatible with the psychologic and
neuropsychologic assessments.
Assessment and Evaluation
A semi-structured interview was performed to collect
sociodemographic and clinical data.
Psychiatric Evaluation
Depression
Depressive symptoms were assessed using a patient-rated
questionnaire and a clinician administrated one, to control for
the bias of self-reporting.
Hamilton Depression Scale (HAM-D)
Depression was assessed using the 17-item HAM-D (Hamilton,
1960). The Hamilton scale was developed for patients
diagnosed with depression, to measure its intensity and
to identify depressive symptoms profiles. We used the
cut-off scores validated for the Portuguese population
(Vaz Serra, 1972).
Beck Depression Inventory (BDI)
Beck published the “Inventory for Measuring Depression”
in 1961, representing the first self-assessment questionnaire
for the study of depression (Beck et al., 1961). The
inventory comprises 21 symptoms that cover multiple
aspects of depressive manifestations, not only affective but
also cognitive, motivational and behavioral. In this study,
the translated and validated Portuguese version was used
(Vaz Serra, 1972).
Anxiety
Hamilton Anxiety Scale (HAM-A)
Anxiety was assessed using the 14-item HAM-A (Hamilton,
1959). The Hamilton scale for anxiety comprises 14 symptoms
covering the most characteristic manifestations of the
anxious syndrome, both in terms of “psychic” (items 1
to 6) and “somatic” (items 6 to 14) symptoms. This scale
is an instrument that has long been validated by several
studies and measured for different Portuguese populations
(Vaz Serra, 1972).
Neuropsychological Evaluation
Mini-Mental State Examination (MMSE)
The MMSE is one of the most widely used brief instruments
for the clinical evaluation of global cognitive state in adults
(Folstein et al., 1975). The MMSE is used for the evaluation
of the mental state and screening of dementia. It is a 30-point
questionnaire, measuring the following areas of cognitive
function: time orientation, spatial orientation, registration,
attention and calculation, recall, language, repetition, and
visual construction. The normative cut-off values for the
Portuguese population adjusted to education were used
(Guerreiro et al., 1994).
Trails Making Test (TMT)
The TMT is an instrument that measures executive functions
(Reitan, 1958). It consists of two parts. In Part A, the
subject is instructed to connect a set of 25 numbers as
fast as possible, while still maintaining accuracy. In Part B,
the subject is instructed to connect numbers sequentially
with letters. Scoring is expressed in terms of the time
(in seconds). The TMT B-A score (calculated as the
difference between TMT-B and TMT-A, to remove the
individual motor speed element from the task and the
composite) is considered a measure of cognitive flexibility
relatively independent of manual dexterity (Misdraji and
Gass, 2010). The Portuguese-validated version was used
(Cavaco et al., 2013).
The Battery of Lisbon for the Assessment of
Dementia (BLAD)
The BLAD is a comprehensive neuropsychological battery
evaluating multiple cognitive domains and validated for
the Portuguese population (Guerreiro, 1998). Tests of
interest for the present study were Digit Span (DS) and
Logical Memory (immediate and delayed recall). DS is a test
that evaluates immediate memory (Digit Span Forward),
working memory (Digit Span Backward), and attention
and concentration (Digit Span Total). Logical Memory
(immediate or delayed recall) evaluates verbal memory and
learning. The participants below education and age-adjusted
values for the Portuguese population (1 standard deviation)
were considered impaired. A cut-off value of 1 standard
deviation was adopted, considering that the use of the cut-
off value of 1.5 standard deviations (Petersen et al., 1999)
could exclude subjects that, from a clinical point of view,
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suffered from mild cognitive impairment (Winblad et al., 2004;
Coelho et al., 2017).
Disease Severity
Aspartate Aminotransferase (AST) to Platelet Ratio
Index (APRI)
This APRI is among the best-validated methods for predicting
HCV progression (Wai et al., 2003). The lower the APRI
score (<0.5), the greater is its negative predictive value
(and ability to rule out cirrhosis); the higher the value
(>1.5), the greater the positive predictive value (and ability
to rule in cirrhosis). The APRI helps with diagnosis based
on the platelet count and AST level. The APRI alone is
likely not sufficiently sensitive to rule out the significant
disease. Some evidence suggests that the use of multiple
indices in combination, such as APRI plus findings on
transient hepatic elastography, or an algorithmic approach, may
result in higher diagnostic accuracy than using APRI alone
(Chou and Wasson, 2013).
Transient Hepatic Elastography (TE)
Liver stiffness measurement by TE was performed according to
published recommendations, using the M probe of FibroScan R©.
The results were expressed in kPa. Only procedures with
at least 10 validated measurements, >60% success rate
and an interquartile range inferior to 25% of the median
value were considered reliable (Pons et al., 2017). The
standard 12.5 kPa for the diagnosis of cirrhosis was used
(Manuel Echevarría et al., 2015).
Statistical Analysis
Results were analyzed using descriptive statistics, including
percentages to describe categorical variables and means and
standard deviations for continuous ones. Spearman correlation
were used to analyze the eventual relation between HCV infection
duration and cognitive/psychological evaluation results.
Demographic, clinical, psychological and neuropsychological
data were analyzed using independent t-tests or linear
regression models for dependent continuous variables, as
normality was achieved in every distribution. Data were
tested for normality using the Shapiro–Wilk test (Ghasemi
and Zahediasl, 2012). The continuous variables were all
standardized to the mean and standard deviation (Z score), and
the reported B values represent the standardized coefficients
or the dimension of the effect. Every B value between 0.2
and 0.5 was considered to be presenting a relevant effect,
and above 0.5 were considered to be of medium dimension.
Although the significance (P-value) is presented and the
significance value was established at a two-tailed threshold
of <0.05, all interpretation is based on the concomitant
values of the coefficient B and the P-value, following
recent discussion on the interpretation bias caused by the
sole interpretation of the latter (Sullivan and Feinn, 2012;
Lakens et al., 2018).
For categorical analysis, chi–squared tests (with the report
of Cochran’s and Mantel-Haenszel statistics (odds ratio) were
used when just one independent variable was being tested or
logistic regression models, when there was more than one
independent variable. The values reported for this analysis are
the ORs, with a reference neutral value of 1. Once again, a
balanced analysis between the odds ratio and the respective
P-value was reported. Odds ratio superior to 1.5 or inferior
to 0.75 were considered as relevant. All the neuropsychological
tests were categorized with the value of 1 for defect and
0 for the absence of defect, and women were categorized
as 1 and men as 0.
The variables related to disease severity (APRI and FibroScan R©
values) are both continuous. Patients with a level of APRI
and FibroScan R© value superior to 2.5 standard deviations of
the respective mean were excluded from the sample, as their
level of disease severity was found to be compromising the
normality of the analysis (Leys et al., 2013). Three males fell
under this condition.
Results are presented controlling for years of substance
dependence (A.Beta1) and the presence or absence of
previous illicit drugs consumption (A.Beta2), as a statistically
significant difference between males and females was found.
Beta (B) scores represent the influence of the gender over
the psychological or neuropsychological measures and
the respective standard deviations for a significance at
95%. Beta values higher than 0.20 represent an effect at
the sample level.
The reported values are ORs, adjusted ORs for the number
of years of substance dependence (A.ORs) and the presence
or absence of illicit drugs consumption (A.OR1); a confidence
interval of 95% was established.
Statistical analyses were performed using IBM SPSS
Statistics 23 for Windows (2016; IBM Corp, Armonk,
NY, United States). The statistical methods of this
study were reviewed by Isabel Flores, senior consultant
in biostatistics.
RESULTS
Demographic and Clinic Characterization
Data
The sample consisted of 86 HCV-infected patients, 63
men, mean age 47.7 ± 9.9 and 23 women (48.0 ± 8.8),
submitted to psychological and neuropsychological
assessments. There were no statistically significant differences
between genders related to age, diagnosis time, civil status,
education, employment, psychiatric antecedents, years of
substance dependence, psychoactive substances, alcohol
use or smoking. There were statistical differences in
substance dependence (89.5% for men and 50% for women,
P < 0.001) (Table 1).
Differences in Psychological and
Neuropsychological Tests by Gender
There were two levels of analyses: the effect of gender on
the continuous variables, and the effect of gender on each
neuropsychological indicator classified in two categories - with
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TABLE 1 | Demographic and personal characterization with gender comparison.
Females, n = 23 Males, n = 63 P
Age 48.0 ± 8.8 47.7 ± 9.9 0.87
Time diagnosis, in yr 9.9 ± 8.6 7.5 ± 7.3 0.24
Education, in yr 9.9 ± 3.3 9.6 ± 4 0.78
Civil status 0.9
Single 18.2% 18.3%
Married 50% 53.3%
Divorced/separated 27.3% 26.7%
Widowed 4.5% 1.7%
Employment 0.83
Employed 54.5% 53.3%
Unemployed 31.8% 38.3%
Medical leave 4.5% 1.7%
Retired 9.1% 6.7%
Psychiatric antecedents 27.3% 11.7% 0.08
Substance dependence 50% 89.5% 0.001a
Psychoactive substances 0.40
Heroin 36.4% 43.4%
Cocaine 9.1% 22.6%
Heroin + Cocaine 18.2% 5.7%
Marijuana 36.4% 28.3%
Years of substance dependence 17.0 ± 9.1 17.2 ± 10.7 0.97
Alcohol 0.41
No 86.4% 78.3%
<10 g/day 13.6% 20%
≥10 g/day 4.5% 3.3%
Smoking 0.55
No 45.5% 33.3%
<10 cigarettes/day 31.8% 43.3%
≥10 cigarettes/day 22.7% 23.3%
aP < 0.01.
or without cognitive defect (Tables 2, 3). A linear regression
model was used to evaluate the gender effect on psychological and
neuropsychological performance.
Regarding gender, it was possible to identify significant
effects on HAM-A (B = 0.64, confidence interval (95% C.I.):
0.17–1.11), with women having higher scores on anxiety. The
same type of effect was found on HAM-D, with women
obtaining a higher significance (B = 0.62, 95% C.I.: 0.14–
1.09) in depression. No difference between genders was
found on the BDI.
In neuropsychological tests, we found significant differences
between gender in executive functions measured by TMT-B
(B = 0.48, 95% C.I.: 0.02–0.97) and in TMT B-A (B = 0.26, 95%
C.I.:−39.2 to−3.7), with women performing worse.
Digit Span Total was also influenced by gender (B = −0.52,
95% C.I.: −1.0 to −0.04), with women having a lower score.
Controlling for years of substance dependence, Digit Span
Total was no longer significant; however, TMT-B and TMT
B-A continued showing gender differences. Controlling for the
presence or absence of substance abuse, only HAM-A and HAM-
D remained significant.
The duration of the infection did not influence psychological
or cognitive results. In fact, we performed a correlation
analysis (spearman) between time since the diagnosis and
neurocognitive/psychological variables and we only found a weak
correlation with TMT B-A (r =−0.252 p = 0.027).
To evaluate the association between gender and
neuropsychological results, categorized as with or without
defect analysis, logistic regression models were used.
In terms of the odds ratio, Digit Span Total shows a
very relevant result, with women having a 7-times higher
possibility of scoring at an abnormal level in this indicator
than men (ORs = 7.07, 95% C.I.: 2.04–24.45). After adjustment,
the ORs remained significant and with a relevant dimension
(A.ORs = 6.86, 95% C.I.: 1.88–24.96; A.OR1 = 5.77, 95% C.I.:
1.53–21.88). For Digit Span Backward, a gender effect was
significant only in ORs (ORs = 3.57, 95% C.I.: 1.31–9.75), but was
lost after adjustments.
Another relevant difference was found in Logical Memory
(immediate recall) OR adjusted for years of substance
dependence, where women showed a higher percentage of
TABLE 2 | Gender effect in psychological and neuropsychological evaluations.
Females,
n = 23
Males,
n = 63
Beta
(95% C.I.)
A.Beta1
(95% C.I.)
A.Beta2
(95% C.I.)
HAM-A 14.3 ± 5.2 10.5 ± 6.0 0.64b (0.17 to 1.11) 0.81b (0.35 to 1.29) 0.72b (0.22 to 1.24)
HAM-D 10.2 ± 4.2 7.3 ± 4.6 0.62a (0.14 to 1.09) 0.74b (0.26 to 1.24) 0.65a (0.13 to 1.16)
BDI 8.7 ± 8.1 7.8 ± 8.4 0.11 (−0.38 to 0.60) 0.12 (−0.39 to 0.63) 0.23 (−3.0 to 0.77)
TMT-A 50.3 ± 6.6 44.6 ± 13.6 0.39 (−0.36 to 0.15) 0.36 (−0.16 to 0.88) 0.24 (−0.28 to 0.77)
TMT-B 134.6 ± 49.8 111.1 ± 49.8 0.48a (0.02 to 0.97) 0.53a (0.02 to 1.05) 0.31 (−0.20 to 0.83)
TMT B-A 84.3 ± 35.2 62.8 ± 35.9 0.26a (−39.2 to −3.7) 0.2a (−39.9 to −2.6) 0.17 (−33.2 to 4.28)
Digit span forward 5.3 ± 1.4 5.9 ± 1.2 −0.44 (−0.92 to 0.04) −0.45 (−0.96 to 0.05) −0.21 (−0.72 to 0.30)
Digit span backward 3.2 ± 0.9 3.7 ± 1.1 −0.44 (−0.92 to 0.04) −0.28 (−0.78 to 0.21) −0.25 (−0.77 to 0.27)
Digit span total 8.6 ± 2.0 9.7 ± 2.1 −0.52a (−1.0 to −0.04) −0.44 (−0.94 to 0.06) −0.27 (−0.77 to 0.23)
Logical memory (immediate recall) 7.5 ± 2.6 6.8 ± 2.6 0.24 (−0.25 to 0.73) 0.33 (−0.18 to 0.85) 0.31 (−0.22 to 0.84)
Logical memory (delayed recall) 6.6 ± 2.1 5.9 ± 2.4 0.03 (−0.52 to 0.46) 0.05 (−0.20 to 0.25) −0.08 (−0.63 to 0.45)
Data is presented as mean ± standard deviation, unless otherwise indicated. aP < 0.005; bP < 0.001. BDI, beck depression inventory; C.I., confidence interval; HAM-A,
hamilton anxiety scale; HAM-D, hamilton depression scale; TMT, trails making test.
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TABLE 3 | Association between gender and neuropsychological results, categorized as with or without defect.
Males (0), n = 63 Females (1), n = 23 ORs (95% C.I.) A.ORs (95% C.I.) A.OR1 (95% C.I.)
TMT-A No defect (0) 83.3% 83% 1.05 0.96 1.07
Defect (1) 16.7% 17% (0.94–3.76) (0.25–3.63) (0.26–4.27)
TMT-B No defect (0) 73.3% 52.2% 2.5 2.48 1.98
Defect (1) 26.7% 47.8% (0.92–6.84) (0.87–7.07) (0.67–5.88)
Digit span forward No defect (0) 88.3% 73.9% 2.7 2.35 2.05
Defect (1) 11.7% 26.1% (0.78–9.04) (0.65–8.44) (0.54–7.86)
Digit span backward No defect (0) 73.3% 43.5% 3.57a 2.49 2.82
Defect (1) 26.7% 56.5% (1.31–9.75) (0.85–7.27) (9.62–8.31)
Digit span total No defect (0) 91.7% 60.9% 7.07b 6.86b 5.77b
Defect (1) 9.3% 29.1% (2.04–24.45) (1.88–24.96) (1.53–21.88)
Logical memory (immediate recall) No defect (0) 26.7% 47.8% 0.39 0.28a 0.39
Defect (1) 73.3% 51.2% (0.14–1.07) (0.09–0.83) (0.13–1.16)
Logical memory (delayed recall) No defect (0) 35% 39% 0.84 0.720 0.66
Defect (1) 65% 61% (0.31–2.25) (0.95–1.02) (0.22–1.20)
aP < 0.005; bP < 0.001. OR, odds ratio; TMT, trails making test.
normal results, presenting a lower possibility of verbal memory
and learning defect (A.ORs = 0.28, 95% C.I.: 0.09–0.83). All the
other indicators showed no relevant differences between genders.
Although not reaching a significant level, ORs in TMT-B and
Digit Span Forward showed a trend to a worse performance
in women, with a probability up to 2.5-times higher for a
defect, facing men.
Disease Severity, Gender, Psychological,
and Neuropsychological Measures
The possibility of a defect was assessed using as predictors
gender, APRI, and FibroScan R© values, as measures of disease
severity. For psychological dimensions, results were obtained
following a multivariable linear regression model and the values
reported are the standardized coefficients of the variables (Beta);
the Nagelkerke (R2) represents a measure of goodness of fit.
For neuropsychological ones, the indicators were codified as
“with defect” (1) and “without defect” (0), and a multiple
logistic binary regression was performed (Table 4). The mean
APRI score for our study population was 0.77 ± 0.68 and
for fibroscan was 8.35 ± 4.32. In APRI, as a predictor
of disease progression, individuals were below the value
representative of cirrhosis (<1.5), as well as in fibroscan
evaluation (<12.5 Kpa).
Results showed that disease severity has no relevant effect on
any score and only gender had a small predictive capacity for
HAM-A (B = 0.62, 95% C.I.: 0.12–1.09; R2 = 0.13) and for HAM-
D (B = 0.56, 95% C.I.: 0.09–1.06; R2 = 0.12), confirming what had
already been reported from the previous analysis.
Digit Span Total provided the most relevant result
(Nagelkerke R2 = 0.23) fully explained by gender, and once
again disease severity seemed not to have influence on this score.
The OR of 8.01 showed that women have a possibility of about 8
times higher for being classified as with defect on this indicator
(B = 8.01, 95% C.I.: 2.01–31.97; R2 = 0.23). In the presence of
disease severity, the Digit Span Backward had a 3.6 higher chance
of being classified as a defect (B = 3.60, 95% C.I.: 1.24–10.49;
R2 = 0.10), in the same line of what has been described before.
TABLE 4 | Association between gender, psychological and categorized
neuropsychological results, controlling for disease severity.
Psychological Gender Beta APRI Beta FibroScan R© Beta R2
(95%C.I.) (95%C.I.) (95%C.I.)
HAM-A 0.62a −0.33 0.05 0.13
(0.12–1.09) (−6.79–0.13) (−0.17–3.44)
HAM-D 0.56a −0.23 0.07 0.12
(0.09–1.06) (−0.64–0.51) (−0.23–2.8)
BDI 0.21 −0.25 0.01 0.04
(−0.26–6.94) (−0.59–0.09) (−0.27–2.35)
Neuropsychological Gender APRI FibroScan R© Nagelkerke
OR OR OR (R2)
TMT-A 0.83 0.39 1.20 0.05
(0.19–3.59) (0.09–1.56) (0.56–2.58)
TMT-B 3.04 0.68 0.51 0.15
(0.99–9.38) (0.27–1.72) (0.24–1.72)
Digit span forward 3.62 0.86 1.46 0.96
(0.95–13.75) (0.27–2.72) (0.58–2.51)
Digit span backward 3.60a 1.0 1.1 0.10
(1.24–10.49) (0.44–2.23) (0.57–1.84)
Digit span total 8.01b 0.81 0.95 0.23
(2.01–31.97) (2.36–2.78) (0.24–1.52)
Logical memory 0.39 0.82 1.04 0.05
(immediate recall)
(0.13–1.13) (0.37–1.80) (0.58–1.87)
Logical memory 0.91 1.48 0.90 0.02
(delayed recall)
(0.31–2.63) (0.65–3.37) (0.51–1.59)
aP < 0.005; bP < 0.001. C.I., confidence interval.
DISCUSSION
Gender research in HCV infection is limited, failing to integrate
the role of gender in neurocognitive syndrome. To the best of our
knowledge, our study is the first to explore the gender effect in
pretreatment HCV-infected patients.
According to our results using clinician-rated instruments
(HAM-A and HAM-D), women presented mild levels of anxiety
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and depression and men showed only mild levels of anxiety. In
the self-evaluation questionnaire (BDI), men and women scored
below the cut-off level for the diagnosis of clinical depression,
ultimately due to a devaluation in emotional self-report.
On neuropsychological performance in pretreatment
HCV-infected patients, the gender effect was even more
evident. Domains, such as attention, concentration, and
memory (short-term and working memory), the ability to
shift strategy, executive functions and visual-spatial working
memory, showed significant differences with women being
more impaired than men. Additionally, when participants
were categorized as with or without defect, women performed
poorly in short-term and in working memory and attention.
This gender effect for executive functions was lost when
controlling for substance dependence but was maintained
and stood out as being significant for attention, concentration
and working memory.
These results can be explained due to the gender impact of the
disease. Previous findings suggest a significantly higher impact
on the quality of life and also a higher burden of the hepatitis
C diagnosis in women (Modabbernia et al., 2013). In fact, in
the general population, the prevalence of depressive disorders is
higher in women (World Health Organization [WHO], 2016),
with a greater burden of mood and anxiety disorders and
a lifetime prevalence around 21% compared to 13% in men
(Kessler et al., 1993).
The impact of psychosocial factors associated with these
disorders are also higher in women, and the risk of developing
mood disorders associated to adverse life events imply several
contributing factors, such as family, work, environmental-
related stressors, poor social support or childhood abuse
(Alexander, 2007). Biological sex-related variables are also a
major determinant of risk for depression, as well as coping with
a chronic disease, such as hepatitis C (Kessler et al., 1993). These
factors might, perhaps, enhance vulnerability to the neurotoxic
effects of the virus in addition to the burden of the disease
(Dannehl et al., 2014). In subsequent analysis, our data replicated
previous findings of gender effect, with women presenting higher
scores in depression and anxiety, even when controlling for
drug use and years of substance dependence. Years of drugs
misuse seems to be important for verbal memory and learning,
with men scoring worse than women. Although these results
highlighted the impact of several years of drug use, they do
not fully explain the impairment in cognitive functions in our
sample. Therefore, these results are in agreement with several
literature reports that have highlighted the CNS toxicity of HCV
(Forton et al., 2001).
Disease severity does not seem to influence gender effect, or
the profile displayed by patients, perhaps due to its low variability
in our sample – Fibroscan (men 8.42± 4.22; women 8.42± 3.98);
APRI (men 0.79± 0.69; women 0.55± 0.31).
The psychological and neurocognitive characterizations of
these patients before treatment assumes particular significance.
The importance of preventing and treating psychological
comorbidities, such as depression and anxiety, can lead to
a better quality of life and better overall functioning during
treatment. Impairments due to psychological or neurocognitive
symptoms are likely to interfere with the way patients experience
and cope with treatment (Barreira et al., 2019). The use of a
personalized and patient-centered approach, promoting a deeper
understanding of disease state and needs, is also desirable
(Schaefer et al., 2012; Modabbernia et al., 2013).
Moreover, factors like gender, depression, psychiatric
diagnosis in general, illicit drug use, HIV coinfection, treatment
regimen, and hemoglobin levels are variables identified as being
significantly and consistently associated with adherence/non-
adherence (Lieveld et al., 2013). According to a review, there is a
tendency for males with HCV to be more adherent than females
(Mathes et al., 2014). Although inconclusive, this tendency
is consistent with recent findings in the wider chronic illness
population. In addition, women were reported as being less
likely to receive long-term medical treatment and to engage in
clinically recommended monitoring (Manteuffel et al., 2014).
These factors are equally relevant in the new treatment landscape
because they are independent of treatment duration.
Furthermore, HCV-related morbidity and mortality
impose a great burden on societies and public health
services. These insights may allow for the design of targeted
interventions being aware of personal variables linked
to the HCV patient profile before treatment, helping to
maximize intervention efficacy and behavior modification,
in order to prevent non-adherence and treatment failure.
Additionally, psychological and neurocognitive factors are
also important for more complex combinations of HCV
enzyme inhibitors, becoming increasingly important for
achieving treatment success as resistant mutations may develop
(Gritsenko and Hughes, 2015).
Research suggests that depression in HCV-infected patients
may be under-diagnosed, thereby increasing the risk of treatment
discontinuation and depression severity, being that HCV itself is
a risk factor for depression (Fialho et al., 2017).
The research presented herein has several limitations. The
convenience sampling method and the relatively small sample
sizes, particularly for women, is a major limitation. Time-
since-diagnosis in a wide range and the non-existence of a
matched control group are also relevant limitations. However,
to compensate for this limitation, we used the values adjusted
for the Portuguese population (education and age-adjusted)
for the tests applied. Also, since the majority of patients
were naïve at the time of sample collection, we did not
control for previous treatments. These results will require
verification in larger samples, and our conclusions must be
interpreted with caution and are not generalizable to all HCV-
infected patients.
Despite these limitations, this study has important strengths.
The “hepatitis C brain syndrome” is a very interesting issue and
there is a lack of studies exploring potential gender differences
regarding this syndrome, using a representative sample. In
contrast to the many studies that have relied solely on self-
reported symptoms scales, this study used both when assessing
the severity of depressive symptoms. The clinician administrated
instruments were applied by a single trained clinical psychologist,
preventing bias on assessment. In addition, this study also
used culturally adapted and validated measures for assessing
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psychological and neuropsychological symptoms, and all
patients were followed in a single center. Lastly, the results
of this study might also have important implications
for clinical practice. These findings are also important
to encourage mental health professionals to take an
active role in HCV treatment in the post-interferon era
(Chasser et al., 2017).
CONCLUSION
In conclusion, chronic HCV infection is known to be
associated with neuropsychiatric dysfunction. Recognition of
neurocognitive symptoms is important before and during
the treatment of these patients, but it is noteworthy that
neurocognitive and neuropsychiatric symptoms (depression,
anxiety, and cognitive disorders) may be associated with direct
HCV neurotoxicity.
According to our investigation, gender seems to have an
influence on depression, anxiety and some of the indicators
of cognitive functions, in chronic HCV-infected patients
before treatment.
DATA AVAILABILITY STATEMENT
The datasets generated for this study are available on request to
the corresponding author.
ETHICS STATEMENT
The studies involving human participants were reviewed and
approved by Centro Hospitalar Universitário Lisboa Norte ethics
committee (Ref. 0536). The patients/participants provided their
written informed consent to participate in this study.
AUTHOR CONTRIBUTIONS
All authors conceived and designed the work, revised the
manuscript critically for important intellectual content, and
approved the final version of the manuscript to be submitted. DB,
RF, and SO conceived of the study and participated in the design
and coordination. RM, MB, and SO reviewed this manuscript. IF
analyzed the data.
REFERENCES
Adinolfi, L. E., Nevola, R., Lus, G., Restivo, L., Guerrera, B., Romano, C., et al.
(2015). Chronic hepatitis C virus infection and neurological and psychiatric
disorders: an overview. World J. Gastroenterol. 21, 2269–2280. doi: 10.3748/wjg.
v21.i8.2269
Adinolfi, L. E., Nevola, R., Rinaldi, L., Romano, C., and Giordano, M. (2017).
Chronic hepatitis C virus infection and depression. Clin. Liver Dis. 21, 517–534.
doi: 10.1016/j.cld.2017.03.007
Alavi, M., Grebely, J., Matthews, G. V., Petoumenos, K., Yeung, B., Day, C., et al.
(2012). Effect of pegylated interferon-α-2a treatment on mental health during
recent hepatitis C virus infection. J. Gastroenterol. Hepatol. 27, 957–965. doi:
10.1111/j.1440-1746.2011.07035.x
Alexander, J. L. (2007). Quest for timely detection and treatment of women with
depression. J. Manag. Care Pharm. 13, S3–S11.
Barreira, D. P., Marinho, R. T., Bicho, M., Fialho, R., and Ouakinin, S. R. S.
(2019). Psychosocial and neurocognitive factors associated with hepatitis
C - implications for future health and wellbeing. Front. Psychol. 9:2666.
doi: 10.3389/fpsyg.2018.02666
Beck, A. T., Ward, C. H., Mendelson, M., Mock, J., and Erbaugh, J. (1961).
An inventory for measuring depression. Arch. Gen. Psychiatry 4, 561–571.
doi: 10.1001/archpsyc.1961.01710120031004
Cavaco, S., Gonçalves, A., Pinto, C., Almeida, E., Gomes, F., Moreira, I.,
et al. (2013). Trail making test: regression-based norms for the portuguese
population. Arch. Clin. Neuropsychol. 28, 189–198. doi: 10.1093/arclin/ac
s115
Chasser, Y., Kim, A. Y., and Freudenreich, O. (2017). Hepatitis C treatment: clinical
issues for psychiatrists in the post-interferon era. Psychosomatics 58, 1–10.
doi: 10.1016/j.psym.2016.09.004
Chou, R., and Wasson, N. (2013). Blood tests to diagnose fibrosis or cirrhosis
in patients with chronic hepatitis C virus infection. Ann. Intern. Med. 158,
807–820. doi: 10.7326/0003-4819-158-11-201306040-00005
Coelho, S., Guerreiro, M., Chester, C., Silva, D., Maroco, J., Paglieri, F., et al. (2017).
Delay discounting in mild cognitive impairment. J. Clin. Exp. Neuropsychol. 39,
336–346. doi: 10.1080/13803395.2016.1226269
Dannehl, K., Rief, W., Schwarz, M. J., Hennings, A., Riemer, S., Selberdinger, V.,
et al. (2014). The predictive value of somatic and cognitive depressive symptoms
for cytokine changes in patients with major depression. Neuropsychiatr. Dis.
Treat. 10, 1191–1197. doi: 10.2147/NDT.S61640
Dirks, M., Pflugrad, H., Haag, K., Tillmann, H. L., Wedemeyer, H., Arvanitis,
D., et al. (2017). Persistent neuropsychiatric impairment in HCV patients
despite clearance of the virus?! J. Viral Hepat. 24, 541–550. doi: 10.1111/jvh.
12674
Ferri, C., Ramos-Casals, M., Zignego, A. L., Arcaini, L., Roccatello, D., Antonelli,
A., et al. (2016). International diagnostic guidelines for patients with HCV-
related extrahepatic manifestations. A multidisciplinary expert statement.
Autoimmun. Rev. 15, 1145–1160. doi: 10.1016/j.autrev.2016.09.006
Fialho, R., Pereira, M., Harrison, N., Rusted, J., and Whale, R. (2017). Co-infection
with HIV associated with reduced vulnerability to symptoms of depression
during antiviral treatment for hepatitis C. Psychiatry Res. 253, 150–157.
doi: 10.1016/j.psychres.2017.03.049
Folstein, M. F., Folstein, S. E., and McHugh, P. R. (1975). Mini-mental
state”. A practical method for grading the cognitive state of patients for
the clinician. J. Psychiatr. Res. 12, 189–198. doi: 10.1016/0022-3956(75)
90026-6
Forton, D. M., Allsop, J. M., Main, J., Foster, G. R., Thomas, H. C., and Taylor-
Robinson, S. D. (2001). Evidence for a cerebral effect of the hepatitis C virus.
Lancet 358, 38–39. doi: 10.1016/S0140-6736(00)05270-3
Gaeta, L., Di Palo, M., Fasanaro, A. M., and Loguercio, C. (2013). Cognitive
dysfunctions in hepatitis C virus (HCV) infection. A mini review. Curr.
Neurobiol. 4, 43–46.
Ghasemi, A., and Zahediasl, S. (2012). Normality tests for statistical analysis: a
guide for non-statisticians. Int. J. Endocrinol. Metab. 10, 486–489. doi: 10.5812/
ijem.3505
Gritsenko, D., and Hughes, G. (2015). Ledipasvir/Sofosbuvir (harvoni): improving
options for hepatitis C virus infection. Pharm. Ther. 40, 256–276.
Grover, V. P. B., Pavese, N., Koh, S.-B., Wylezinska, M., Saxby, B. K., Gerhard,
A., et al. (2012). Cerebral microglial activation in patients with hepatitis
c: in vivo evidence of neuroinflammation. J. Viral Hepat. 19, e89–e96.
doi: 10.1111/j.1365-2893.2011.01510.x
Guerreiro, M. (1998). Contributo da Neuropsicologia para o Estudo das Deme˛ncias.
Lisboa: Faculdade de Medicina de Lisboa.
Guerreiro, M., Silva, A., Botelho, M., Leitão, O., Castro Caldas, A., and Garcia,
C. (1994). Adaptação à população portuguesa da tradução do “Mini Mental
State Examination” (MMSE). Rev. Port. Neurol. 1, 9–10. doi: 10.1017/
CBO9781107415324.004
Hamilton, M. (1959). The assessment of anxiety satates by rating. Br. J. Med.
Psychol. 32, 50–55. doi: 10.1111/j.2044-8341.1959.tb00467.x
Frontiers in Psychology | www.frontiersin.org 8 October 2019 | Volume 10 | Article 2317
fpsyg-10-02317 October 15, 2019 Time: 12:41 # 9
Barreira et al. Hepatitis C Pretreatment: Gender and Cognition
Hamilton, M. (1960). A rating scale for depression. J. Neurol. Neurosurg. Psychiatry
23, 56–62. doi: 10.1136/jnnp.23.1.56
Harris, M., and Rhodes, T. (2013). Hepatitis C treatment access and uptake for
people who inject drugs: a review mapping the role of social factors. Harm
Reduct. J. 10:7. doi: 10.1186/1477-7517-10-7
Kessler, R. C., McGonagle, K. A., Swartz, M., Blazer, D. G., and Nelson, C. B. (1993).
Sex and depression in the national comorbidity survey I: lifetime prevalence,
chronicity and recurrence. J. Affect. Disord. 29, 85–96. doi: 10.1016/0165-
0327(93)90026-G
Kuhn, T., Sayegh, P., Jones, J. D., Smith, J., Sarma, M. K., Ragin, A., et al. (2017).
Improvements in brain and behavior following eradication of hepatitis C.
J. Neurovirol. 23, 593–602. doi: 10.1007/s13365-017-0533-0
Lakens, D., Adolfi, F. G., Albers, C. J., Anvari, F., Apps, M. A. J., Argamon, S. E.,
et al. (2018). Justify your alpha. Nat. Hum. Behav. 2, 168–171. doi: 10.1038/
s41562-018-0311-x
Leys, C., Ley, C., Klein, O., Bernard, P., and Licata, L. (2013). Detecting outliers:
do not use standard deviation around the mean, use absolute deviation
around the median. J. Exp. Soc. Psychol. 49, 764–766. doi: 10.1016/j.jesp.2013.
03.013
Lieveld, F. I., van Vlerken, L. G., Siersema, P. D., and van Erpecum, K. J. (2013).
Patient adherence to antiviral treatment for chronic hepatitis B and C: a
systematic review. Ann. Hepatol. 12, 380–391. doi: 10.1016/s1665-2681(19)
31000-2
Lowry, D., Coughlan, B., McCarthy, O., and Crowe, J. (2010). Investigating health-
related quality of life, mood and neuropsychological test performance in a
homogeneous cohort of Irish female hepatitis C patients. J. Viral Hepat. 17,
352–359. doi: 10.1111/j.1365-2893.2009.01188.x
Manteuffel, M., Williams, S., Chen, W., Verbrugge, R. R., Pittman, D. G., and
Steinkellner, A. (2014). Influence of patient sex and gender on medication use,
adherence, and prescribing alignment with guidelines. J. Womens Health 23,
112–119. doi: 10.1089/jwh.2012.3972
Manuel Echevarría, J., León, P., Pozo, F., and Avellón, A. (2015). EASL-ALEH
clinical practice guidelines: non-invasive tests for evaluation of liver disease
severity and prognosis. J. Hepatol. 63, 237–264. doi: 10.1016/j.jhep.2015.
04.006
Mathes, T., Antoine, S.-L., and Pieper, D. (2014). Factors influencing adherence
in Hepatitis-C infected patients: a systematic review. BMC Infect. Dis. 14:203.
doi: 10.1186/1471-2334-14-203
Misdraji, E. L., and Gass, C. S. (2010). The trail making test and its
neurobehavioral components. J. Clin. Exp. Neuropsychol. 32, 159–163.
doi: 10.1080/13803390902881942
Modabbernia, A., Poustchi, H., and Malekzadeh, R. (2013). Neuropsychiatric and
psychosocial issues of patients with hepatitis C infection: a selective literature
review. Hepat. Mon. 13, 1–9. doi: 10.5812/hepatmon.8340
Monaco, S., Mariotto, S., Ferrari, S., Calabrese, M., Zanusso, G., Gajofatto, A.,
et al. (2015). Hepatitis C virus-associated neurocognitive and neuropsychiatric
disorders: advances in 2015. World J. Gastroenterol. 21, 11974–11983.
doi: 10.3748/wjg.v21.i42.11974
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., and
Kokmen, E. (1999). Mild cognitive impairment: clinical characterization and
outcome. Arch. Neurol. 56, 303–308.
Polaris Observatory, H. C. V., Collaborators, S., Zeuzem, S., Manns, M., Altraif,
I., Duberg, A.-S., et al. (2017). Global prevalence and genotype distribution of
hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol.
Hepatol. 2, 161–176. doi: 10.1016/S2468-1253(16)30181-9
Pons, M., Santos, B., Simón-Talero, M., Ventura-Cots, M., Riveiro-Barciela,
M., Esteban, R., et al. (2017). Rapid liver and spleen stiffness improvement
in compensated advanced chronic liver disease patients treated with
oral antivirals. Therap. Adv. Gastroenterol. 10, 619–629. doi: 10.1177/
1756283X17715198
Reitan, R. M. (1958). Validity of the trail making test as an indicator of organic
brain damage. Percept. Mot. Skills 8, 271–276. doi: 10.2466/pms.1958.8.3.271
Schaefer, M., Capuron, L., Friebe, A., Diez-Quevedo, C., Robaeys, G., Neri, S., et al.
(2012). Hepatitis C infection, antiviral treatment and mental health: a European
expert consensus statement. J. Hepatol. 57, 1379–1390. doi: 10.1016/j.jhep.2012.
07.037
Smith, M. A., Chan, J., and Mohammad, R. A. (2015). Ledipasvir-sofosbuvir:
interferon-/ribavirin-free regimen for chronic hepatitis C virus infection. Ann.
Pharmacother. 49, 343–350. doi: 10.1177/1060028014563952
Sullivan, G. M., and Feinn, R. (2012). Using effect size—or why the P value is not
enough. J. Grad. Med. Educ. 4, 279–282. doi: 10.4300/JGME-D-12-00156.1
Vaz Serra, A. (1972). A Influe˛ncia da Personalidade no Quadro Clínico Depressivo.
Coimbra: Universidade de Coimbra.
Wai, C., Greenson, J. K., Fontana, R. J., Kalbfleisch, J. D., Marrero, J. A.,
Conjeevaram, H. S., et al. (2003). A simple noninvasive index can predict both
significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology
38, 518–526. doi: 10.1053/jhep.2003.50346
Weissenborn, K., Krause, J., Bokemeyer, M., Hecker, H., Schüler, A., Ennen,
J. C., et al. (2004). Hepatitis C virus infection affects the brain-evidence from
psychometric studies and magnetic resonance spectroscopy. J. Hepatol. 41,
845–851. doi: 10.1016/j.jhep.2004.07.022
Wie˛dłocha, M., Marcinowicz, P., Sokalla, D., and Stañczykiewicz, B. (2017). The
neuropsychiatric aspect of the HCV infection. Adv. Clin. Exp. Med. 26, 167–175.
doi: 10.17219/acem/37787
Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L.-
O., et al. (2004). Mild cognitive impairment - beyond controversies, towards
a consensus: report of the international working group on mild cognitive
impairment. J. Intern. Med. 256, 240–246. doi: 10.1111/j.1365-2796.2004.01
380.x
World Health Organization [WHO], (2016). Disease Burden and Mortality
Estimates. Geneva: WHO, 1–65.
Yarlott, L., Heald, E., and Forton, D. (2017). Hepatitis C virus infection, and
neurological and psychiatric disorders – A review. J. Adv. Res. 8, 139–148.
doi: 10.1016/j.jare.2016.09.005
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2019 Barreira, Marinho, Bicho, Flores, Fialho and Ouakinin. This is an
open-access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) and the copyright owner(s) are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Psychology | www.frontiersin.org 9 October 2019 | Volume 10 | Article 2317
